Quanterix Corp stands out in life sciences through its proprietary Simoa technology, enabling detection of proteins at femtomolar levels. The 2025 acquisition of Akoya Biosciences enhances its portfolio with spatial biology capabilities, expanding market reach. Despite revenue stability near $138 million in 2024-25, the company faces deepening net losses due to R&D expansion and integration costs, with operating income plunging over 138% year-over-year. Operational challenges such as lengthy sales cycles, product quality risks, and intellectual property litigation remain significant. Upcoming FDA review milestones for its Alzheimer’s blood test and successful Akoya integration will be pivotal for growth prospects.